NCT03500419

Brief Summary

The objective of the current study is to evaluate the efficacy of a novel, class I (ie. lowest risk, clinical studies not required) medical penile traction device in preventing loss of penile length in men undergoing robotic-assisted prostatectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
82

participants targeted

Target at P25-P50 for not_applicable prostate-cancer

Timeline
Completed

Started Mar 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 23, 2018

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

April 9, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 18, 2018

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 28, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 28, 2020

Completed
10 months until next milestone

Results Posted

Study results publicly available

October 20, 2021

Completed
Last Updated

October 20, 2021

Status Verified

September 1, 2021

Enrollment Period

2.8 years

First QC Date

April 9, 2018

Results QC Date

September 28, 2021

Last Update Submit

September 28, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Penile Length

    Stretched penile length measured in centimeters from pubic symphysis to glanular corona

    Baseline, 6 months

Secondary Outcomes (5)

  • Erectogenic Therapy Use

    6 months

  • Intracavernosal Injections

    6 months

  • Change in Erectile Function Domain of International Index of Erectile Function (IIEF)

    baseline, 6 months

  • Change in Intercourse Satisfaction Domain of International Index of Erectile Function (IIEF)

    Baseline, 6 months

  • Change in Overall Satisfaction Domain of International Index of Erectile Function (IIEF)

    Baseline, 6 months

Study Arms (2)

Control

ACTIVE COMPARATOR

No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.

Other: No treatment

Group AB - PTT 1-2x daily x 5-7 days/week x 5 months

EXPERIMENTAL

Men will utilize penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months.

Device: RestoreX

Interventions

RestoreXDEVICE

PTT - Penile traction therapy in the straight position.

Group AB - PTT 1-2x daily x 5-7 days/week x 5 months

Control group. No treatment will be given for the 6 months post-prostatectomy

Control

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Undergoing robotic prostatectomy
  • Seen in the post-prostatectomy rehab clinic

You may not qualify if:

  • Urethral complications from prostatectomy at the time of baseline visit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Links

MeSH Terms

Conditions

Prostatic NeoplasmsPenile Diseases

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Results Point of Contact

Title
Matthew (Matt) J. Ziegelmann, M.D.
Organization
Mayo Clinic

Study Officials

  • Matthew Ziegelmann, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 9, 2018

First Posted

April 18, 2018

Study Start

March 23, 2018

Primary Completion

December 28, 2020

Study Completion

December 28, 2020

Last Updated

October 20, 2021

Results First Posted

October 20, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations